Deep Brain Stimulation Impact on Social and Occupational Functioning in Parkinson's Disease with Early Motor Complications. by Stoker, Valerie et al.
Deep Brain Stimulation Impact on Social
and Occupational Functioning in
Parkinson’s Disease with Early Motor
Complications
Valerie Stoker, MPH,1 Paul Krack, MD, PhD,2 Lisa Tonder, MS,1 Gillian Barnett, MSc,1 Isabelle Durand-Zaleski, MD, PhD,3
Alfons Schnitzler, MD, PhD,4 Jean-Luc Houeto, MD, PhD,5 Lars Timmermann, MD, PhD,6 Joern Rau, MSc,7 Carmen Schade-Brittinger, BSC,7
Marie Vidailhet, MD, PhD,8 and Günther Deuschl, MD, PhD,9,* EARLYSTIM Study Group†
ABSTRACT: Background: Deep brain stimulation (DBS) improves motor symptoms and quality of life in patients
with Parkinson’s disease (PD) and early motor complications, suggesting that DBS could be prescribed to the
working-age PD population.
Objectives: To investigate the effect of DBS compared with best medical therapy (BMT) on social, psychosocial,
and occupational functioning in patients with PD ≤60 years of age with early motor complications, its
correlates, and possible underlying rationale.
Methods: Methods included analyses of the Social and Occupational Functioning Assessment Scale, Scales for
Outcomes for Parkinson’s–Psychosocial, Professional Fitness, Starkstein Apathy Scale, and Schwab and
England Activities of Daily Living Scale from the EARLYSTIM study.
Results: Compared with BMT, DBS resulted in significantly greater improvements from baseline through 24 months
in social,occupational, and psychosocial functioning. Yet, work status in the 2 groups did not differ at baseline and
24 months. Physicians reported a significantly higher percentage of patients in the BMT group unable to work at
24 months relative to baseline compared with the DBS group. Apathy was significantly worse in patients for whom
physicians overrated ability to work when compared with patients’ own ratings than in the group of patients who
physicians’ ability to work ratings were comparable to, or worse than, patients’ self-ratings of ability to work.
Conclusions: For patients aged ≤60 years with PD and early motor complications, DBS provided significant
improvements in social, occupational, and psychosocial function, but not in the actual work engagement
compared with BMT at 2 years. Apathy may impact ability to work.
Deep brain stimulation (DBS) of the subthalamic nucleus is an
established treatment for patients with Parkinson’s disease (PD)
with fluctuations and dyskinesia refractory to medical therapy.1–6
Eligible patients typically undergo DBS implantation 11 to
13 years (mean values) after medical therapy has been pre-
scribed,1–3,7 when severe motor complications have markedly
reduced quality of life and patients have reached retirement age.
However, with a disease prevalence of 107 per 100,000 persons
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aged 50 to 59 years,8 and 32% of patients with PD with disease
onset before the age of 59 years,9 PD is not uncommon among
working-age individuals. Indeed, more than half (56%) of non-
retired persons with PD onset before the age of 50 living in the
United Kingdom were unemployed as a result of disability,10
and persons with PD retire 4 to 7 years earlier than the general
population.11
PD reduces productivity while at work (presenteeism) and
increases absenteeism from work and work activity impairment
compared with controls.12 In addition, diminished capacity to
work contributes to the financial burden of PD with up to 49% of
the total cost arising from the indirect cost of reduced work capac-
ity and early retirement in the United States and Europe.13,14
When evaluating new health care technologies, reimburse-
ment agencies have advocated the adoption of a broad societal
perspective in economic analyses by considering the cost of
productivity loss and early retirement in complementary ana-
lyses by agencies in France and Germany and in primary ana-
lyses in Scandinavia and the Netherlands.15,16 To date, the
societal impact of DBS has only been described in the results of
a single-center retrospective study in Hungary17 showing that
for employed patients with PD, DBS may help preserve work-
ing capability.
The EARLYSTIM study was designed to evaluate the impact
of DBS compared with best medical therapy (BMT) on quality
of life, the primary endpoint, and multiple secondary endpoints
for patients with PD with recent onset motor complications
(≤3 years), preserved psychosocial competence, and a younger
age (≤60 years) to reflect a working-age population.18 To address
knowledge gaps, the objectives of this secondary analysis were to
investigate the effect of DBS compared with BMT on social,
psychosocial, and occupational functioning in working-age
patients with PD with early motor complications, its correlates,
and possible underlying rationale.
Methods
The design and main results of the EARLYSTIM study
(NCT00354133) are described elsewhere.18,19 In brief, 251
patients in France and Germany with PD and early levodopa-
induced motor complications with a mean age of 52 years who
were, on average, 7.5 years post-PD onset, were randomized to
DBS plus BMT (the DBS group) or BMT alone (the BMT
group). Patients were assessed at baseline and 5, 12, and finally,
24 months after randomization; albeit some endpoints were only
at assessed at baseline and 24 months.
For this analysis, endpoints assessed in the EARLYSTIM
study, including the Social and Occupational Functioning
Assessment Scale (SOFAS), the Scales for Outcomes for
Parkinson’s–Psychosocial (SCOPA-PS), and the Professional
Fitness questionnaire (to determine ability to work and work
status), were analyzed.
Correlations between social and occupational functioning and
activities of daily living (using the modified Schwab and England
Activities of Daily Living Scale [Schwab and England]) and
patient apathy (using the Starkstein Apathy Scale) by categories
of physician versus patient ratings of ability to work were also
analyzed. Additional results of SCOPA-PS, the Starkstein Apathy
Scale, and Schwab and England are briefly reported elsewhere.19
Instruments with the exception of the Professional Fitness ques-
tionnaire have acceptable psychometric properties in terms of
reliability and validity.
SOFAS is a quantitative scale which assesses psychosocial com-
petence in terms of social and occupational functioning.20 It is
scored as a percentage (in increments of 10 percentage points) on
a continuum ranging from grossly impaired functioning (persis-
tent hygiene problems) to excellent functioning (superior func-
tioning in a wide range of activities). The SCOPA-PS was
administered at study visits to assess psychosocial constraints
brought about by PD in the previous month.21 It is scored on a
scale of 0 to 33; a higher score indicates worse functioning. The
Professional Fitness questionnaire requests patients and physicians
select from the following 4 categories of ability to work: work
full-time without limitations, work with limitations but full-
time, work with significant limitations in a part-time position,
and not able to work. Actual work status at all time points was
also collected with the Professional Fitness questionnaire where
work was defined as engagements with salary and work-like
engagements without salary (eg, taking care of grandchildren on
a regular basis replacing a profession). Patients were also
instructed to classify their work status into the following catego-
ries based on the German social security system: full-time work,
half-time work, less than half-time work, or not working.22 The
patient-reported Starkstein Apathy Scale comprises 14 questions,
each is scored from 0 to 3, with a maximum of 42 points; a
higher score indicates more severe apathy.23 The Schwab and
England is an assessment of activities of daily living relative to
complete independence based on an interview referring to the
week before the study visit. Responses reflect the “best” state
and “worst’ state and scores range from 0% (complete depen-
dence) to 100% (complete independence).24
Statistical Methods
Mean change in SOFAS and SCOPA-PS scores at 24 months
were compared with baseline within each treatment group and
between groups using mixed model statistical analysis with a nor-
mality assumption, the baseline value for baseline adjustment,
main effects for group, time, a group-by-time interaction, center
as random effect, and a generalized covariance matrix (to account
for serial dependency among observations).
Responses to the Professional Fitness questions were
converted to a binary outcome of “unable to work” versus “able
to work” for the between-group comparison at 24 months, and
logistic regression analysis was performed using binomial assump-
tions, a logit link, and main effects for group, time, a group-by-
time interaction, and an exchangeable covariance structure. The
difference between the physician and patient ratings of ability to
work was converted into a categorical variable with 3 levels:
physician rating of ability to work is better than the patient
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rating, physician and patient ratings of ability to work are the same,
and physician rating of ability to work is worse than the patient rat-
ing. A proportional odds model with a cumulative logit link was
used for the analysis with factors for group, visit, and a group-by-
visit interaction. The physician versus patient ratings for ability to
work were evaluated over time with an added covariate of the Sta-
rkstein Apathy Scale score at 24 months to investigate the impact of
apathy on physicians’ ratings of professional fitness relative to
patients’ self-assessment. The correlation between Schwab and
England and SOFAS scores at 24 months was analyzed using the
Pearson product-moment correlation coefficient. The proportion of
patients employed at 24 months and those working at baseline and
24 months for the DBS versus BMT groups were compared using a
chi-square test.
Analysis of the social and occupational endpoints (SOFAS and
SCOPA-PS) included the intention-to-treat cohort, whereas the
analysis of Professional Fitness and the correlation between SOFAS
and Schwab and England included the completers’ data set.
Generalized least squares estimations with standard errors, and
95% confidence intervals and P values were calculated. Adjust-
ments for multiple comparisons were not implemented. Statisti-
cal significance was identified as a P value ≤ 0.05.
Results
Baseline demographic and clinical characteristics of the inten-
tion-to-treat cohort are described elsewhere.19 In summary, 124
patients were assigned to DBS (97% received DBS therapy and
completed the study), and 127 patients were assigned to BMT
(98% received BMT and 97% completed the study). SOFAS was
used to determine social and occupational functioning as one
inclusion criterion at study enrollment, with impairment of 51%
to 80% (ie, moderate difficulty to slight impairment in social
functioning) required. Baseline demographic and clinical charac-
teristics did not differ significantly between the treatment groups,
and baseline employment rates (part-time or full-time) in the
DBS (62.6%) and BMT groups (61.4%) were comparable.
Social and occupational functioning (SOFAS score) improved
by 11% from baseline to 24 months (P < 0.05) in the DBS
group, a mean category change from “some difficulty” to “slight
impairment.” In the BMT group, it decreased by 3% (P > 0.05)
through 24 months; however, the BMT group had maintained
its baseline mean category status of “some difficulty,” which
refers to the categorical assessment based on a score of 61% to
70%, whereas slight impairment is 71% to 80%, and superior
functioning 91% to 100%. Compared with BMT, DBS resulted
in a greater improvement from baseline through 24 months in
social and occupational functioning (mean ± standard error [SE]
difference, 9.8 ± 1.9 points; P < 0.001) (Fig. 1 and Table 1).
There were positive moderate correlations between the best and
worst Schwab and England and SOFAS scores at 24 months for
both treatment groups (r, range, 0.47–0.64; P < 0.0001).
Psychosocial functioning, measured using the SCOPA-PS,
improved by 28% and 3% from baseline to 24 months in the
DBS group (mean ± SE, −2.5 ± 0.5; P < 0.05) and the BMT
group (mean ± SE, −0.5 ± 0.5; P > 0.05), respectively. Com-
pared with BMT, DBS resulted in a greater improvement from
baseline through 24 months in psychosocial functioning (mean
difference ± SE, −2.1 ± 0.7; P = 0.023) (Fig. 2 and Table 1).
At 24 months, work status (unemployed vs. full-time
employed) was not significantly different between the DBS
FIG. 1. Change in SOFAS Scale. Higher values indicate an improvement as compared with baseline. Data are means ± standard error
estimated by mixed model regression. BMT, best medical therapy; DBS, deep brain stimulation; SOFAS, Social and Occupational
Functioning Assessment Scale.
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(44.2%) and BMT (40.2%) groups. Physicians consistently rated
patients as more able to work compared with how patients rated
themselves (Fig. 3). When physicians’ subjective assessment of
patients’ ability to work in response to the Professional Fitness
questionnaire was converted to a binary outcome (“unable to
work” vs. “able to work”), there was an increase in the percent-
age of patients rated as unable to work over 24 months in the
BMT group (P < 0.001) compared with no change in the DBS
group (P = 0.789), with a difference between treatment groups
at 24 months (P = 0.003) in favor of DBS (Fig. 4). Patient self-
assessment of being “unable to work” showed a worsening over
24 months in the BMT group (27% vs. 36%; P = .023) and no
change in the DBS group (22% vs. 28%; P = 0.154). There was
no difference in patient self-assessment between treatment groups
at 24 months (P = 0.586).
Differences in ability to work ratings between physicians and
patients at 24 months were further explored in analysis of
patients’ apathy measured with the Starkstein Apathy Scale.
Results showed significantly worse patient-reported apathy in
the group comprising patients whose physician ratings of ability
to work were more than their own ratings compared with the
patient group in which physicians provided the same ability to
work ratings as the patients (Fig. 5). In addition, significantly
worse patient-reported apathy was also recorded in the group in
which physicians rated patients more able to work than patients
rated themselves compared with the group with physicians who
rated patients less able to work than patients rated themselves.
Discussion
To the best of our knowledge, this is the first publication of
social and occupational outcomes of DBS compared with BMT
for patients with PD ≤60 years of age with early motor compli-
cations based on data from a randomized controlled trial
TABLE 1 Change from baseline to 24 months—SOFAS and SCOPA-PS
Baseline
Within-Treatment Change from
Baseline to 24 Months
Between-Treatment Change from
Baseline to 24 Months
DBS BMT DBS BMT Differences
Endpoint n Mean ± SE N Mean ± SE Mean ± SE (% Change) Mean ± SE (% Change) Mean ± SE; 95% CI Significance
SOFASa 124 69.5 ± 1.6 127 69.3 ± 1.6 7.8 ± 1.3 (11)c −2.02 ± 1.3 (−3) 9.8 ± 1.9; 6.3–13.5 P < 0.001
SCOPA-PSb 124 9.1 ± 0.5 127 9.0 ± 0.5 −2.5 ± .0.5 (−28)c −0.4 ± 0.5 (−3) −2.1 ± 0.7; −3.9 to −0.4 P = 0.023
aPositive change indicates improvement.
bNegative change indicates improvement.
cWithin-group change, P ≤ 0.05.
Abbreviations: SOFAS, Social and Occupational Functioning Assessment Scale; SCOPA-PS, Scales for Outcomes for Parkinson’s–Psychosocial;
DBS, deep brain stimulation; BMT, best medical therapy; SE, standard error; CI, confidence interval.
FIG. 2. Change in SCOPA-PS score. Lower values indicate an improvement as compared with baseline. Data are means ± standard error
estimated by mixed model regression. BMT, best medical therapy; DBS, deep brain stimulation; SCOPA-PS, Scales for Outcomes for
Parkinson’s–Psychosocial.
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(EARLYSTIM), showing that DBS significantly improved social,
occupational, and psychosocial functioning from baseline
through 2 years compared with BMT. The improvement in
social and occupational functioning with DBS was also clinically
meaningful with patients moving from being categorized as hav-
ing “some difficulty” to a “slight impairment.” The actual work
status did not differ between the BMT and DBS groups at base-
line and after 24 months. Physicians reported that BMT group
patients’ ability to work decreased over 2 years, whereas patients
in the DBS group maintained their baseline professional fitness,
with a statistically significant between-group difference at
24 months. Another key finding was that physicians viewed
patients as being more able to work than patients viewed
themselves.
This controlled study also offers the possibility to compare a
large group of patients randomized to DBS or BMT for psycho-
social outcomes and employment status. First, we found that of
the patients who were working at baseline in the DBS group,
69% were successfully retained in the workforce compared with
54% in the BMT group at 24 months (P value of 0.052, consid-
ering that this group of patients who were working at baseline
was 60.2% of the overall cohort, this analysis was not powered to
detect a meaningful treatment difference). In EARLYSTIM,
with a mean age of 52 years and a 63% employment rate at base-
line, despite multiple clinical benefits with DBS 2 years
postimplantation,19 the employment rate had decreased to 44%.
There may be other economic or societal factors influencing
actual work status, as even in the general population, employ-
ment rates are decreasing with increasing age. The employment
rate in Germany and France among the general population aged
25 to 54 years of age in 2018 was 88%, whereas among those
aged 55 to 64 years, 75% and 56% were employed,
respectively.19
In contrast, the ratings by both patients and physicians for
ability to work were higher than the actual employment status,
with the physicians’ ratings being higher than the patients’ rat-
ings. The difference between actual employment status and the
patients’ ratings may be attributed to a lack of opportunity, as it
is difficult for persons aged >50 years to find suitable employ-
ment in France and Germany, where EARLYSTIM was con-
ducted. The difference between the physicians’ and the patients’
assessments may indeed reflect factors outside the mere physical
and mental abilities of the patients. This has been assessed with
different questionnaires exploring psychological and social
variables.
Results from our analyses of SOFAS and the Schwab and
England, both measures of disability, support greater indepen-
dence for activities of daily living with DBS treatment.19 As
expected, social and occupational functioning and ability to per-
form every day activities were positively correlated; as one
improves, so does the other.
Social anxiety and social phobia, common among persons with
PD,25,26 contribute to reduced social participation27 and are strongly
related to the impact of reduced mobility on quality of life.28
FIG. 3. Change in actual work status and ability to work. BMT, best medical therapy; DBS, deep brain stimulation. *Change between
groups from baseline to 24 months P ≤ 0.05.
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The improvement in psychosocial functioning (SCOPA-PS) in
the DBS group compared with the BMT group is consistent
with the findings of social and occupational functioning
(SOFAS). Another psychosocial impact of PD is the stigma sub-
score of the Parkinson’s Disease Questionnaire-39 that improved
most with DBS, as described in the EARLYSTIM study main
publication.19 A possible consequence of stigma is shame, a self-
perception of inadequacy and violation of the norm.29 Shame is
a relevant psychosocial impact of PD that likely also contributes
to a patient’s ability to work.
Analysis of data in the national patient registry in Denmark
showed that 8 years before PD was diagnosed (typically based on
motor symptoms) there were significantly fewer patients
employed compared with non-PD controls.30,31 This may reflect
the impact of premotor symptoms of PD such as anxiety, depres-
sion, and fatigue.31 In addition, fatigue and slowness are associ-
ated with the inability of persons with PD to successfully
continue employment.11
Apathy and nonmotor outcomes may impact employability, as
interpreted by physicians and patients. Apathy is part of a
hypodopaminergic postoperative withdrawal syndrome that also
includes depression and anxiety.32,33 A clinician may be guided
by the relative absence of motor symptoms such as tremor or
akinesia, whereas the patient’s judgment may be more influenced
by subjective lack of motivation (apathy) or a subjective feeling
of fatigue (apathy) or more generally by the presence of a
hypodopaminergic syndrome, which has been shown to occur as
part of a dopamine withdrawal syndrome.32,33 Importantly, if
recognized, this withdrawal syndrome is reversible with appro-
priate treatment of apathy (eg, by introducing a D2/D3 dopa-
mine agonist).34 Another important message from this analysis
relates to the rationale for the difference between physician and
patient assessment of the patient’s ability to work and the rela-
tionship with patient-reported apathy in the current study. One
study35,36 reported results from a series of 29 patients who had
FIG. 4. Change in professional fitness ratings—“unable to work.” BMT, best medical therapy; DBS, deep brain stimulation. # Within-group
change, P ≤ 0.05; *between-group change, P ≤ 0.05.
FIG. 5. Starkstein Apathy Scale scores by physician versus
patient responses to the ability to work at 24 months. Higher
score indicates more severe apathy. Data are means ± standard
error estimated by mixed model regression. *Difference
between categories P ≤ 0.05.
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received DBS at an average age of 52 years resulting in an
improvement in motor function but not psychosocial adjustment
after 18 to 24 months. They interpreted this finding from a psy-
chological perspective as the result of the patient’s maladaptation
to PD with this therapy. The patient response to the Professional
Fitness ability to work questionnaire in EARLYSTIM could be
based on underlying apathy interpreted via the patient ‘s own
employability rating, but not the physicans’, resulting in the phy-
sician being happy but the patient less so. However, although
interpretation was mostly psychological, a possible explanation of
this discrepancy between physician and patient estimation of
employability may be attributed to the hypodopaminergic syn-
drome, including apathy based on the Starkstein Apathy Scale
and the apathy in the Ardouin scale.37 The latter reported no
substantial increase in hypodopaminergic disorders in patients
assigned DBS compared with those BMT from the
EARLYSTIM study.
Importantly, discrepancies between patient-reported and phy-
sician-reported treatment effects and the importance of deter-
mining the latter from the patient’s perspective versus the
physician’s subjective interpretation have long been recognized.38
Further work on assessing the societal impact of DBS should also
consider the recent suggestion to assess broader concepts of “par-
ticipation” in society beyond the ability to work to fully capture
the societal impact of disease and treatments.39,40
There are limitations in the interpretation of the analyses as
the Professional Fitness questionnaire used has not undergone
clinimetric evaluation. No other instruments were available
when this trial was designed, and this questionnaire was devel-
oped specifically to address the question whether DBS can have
an impact on work status, a question raised by an earlier study.41
Still, this analysis reinforces the value of patient-reported out-
comes and explains some important differences with physician-
reported outcomes. A further limitation is that a psychological
rationale for the differences in the ability to work such as a mod-
ification in patients’ lifestyle related to changes in coping strate-
gies rather than changes in motivation was not evaluated in this
study.
For patients aged ≤60 years presenting with early motor com-
plications of PD, DBS provided significant improvements in
social, occupational, and psychosocial functioning from baseline
through 2 years compared with BMT. Actual employment status
was not different between the 2 groups at 24 months and con-
trasts with the differences in physician versus patient rating of
inability to work which was associated with increased rates of
apathy. During postoperative management of DBS in PD, sub-
jective inability to work may be positively influenced by man-
agement of dopaminergic medications,34 potentially resulting in
a “happy doctor with a happy patient.”
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